Cargando…

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire (PAH-SYMPACT) is the only pulmonary arterial hypertension-specific patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Frantz, Robert P., Chin, Kelly M., Zhao, Carol, Flynn, Megan, Badesch, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238840/
https://www.ncbi.nlm.nih.gov/pubmed/32489644
http://dx.doi.org/10.1177/2045894020923957
_version_ 1783536610017542144
author Frantz, Robert P.
Chin, Kelly M.
Zhao, Carol
Flynn, Megan
Badesch, David
author_facet Frantz, Robert P.
Chin, Kelly M.
Zhao, Carol
Flynn, Megan
Badesch, David
author_sort Frantz, Robert P.
collection PubMed
description Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire (PAH-SYMPACT) is the only pulmonary arterial hypertension-specific patient-reported outcomes instrument developed and validated in accordance with the US Food and Drug Administration guidance on patient-reported outcomes development. The PAH-SYMPACT tool measures pulmonary arterial hypertension-related symptoms and impact of pulmonary arterial hypertension on daily life. Symptoms are reported each day for seven consecutive days, and the impact of pulmonary arterial hypertension over one week is recalled and reported on day 7; however, daily symptom reporting may overburden patients and healthcare resources, limiting the practicality of PAH-SYMPACT outside of clinical trials. To determine the practicability of an abridged version of PAH-SYMPACT for which all reporting is completed on one day, symptom data from the SYMPHONY trial (NCT01841762; PAH-SYMPACT validation study) were retrospectively analyzed to assess whether symptoms reported on each day correlated with the weekly average and whether one-day symptom scores were sensitive to disease severity. Correlation coefficients comparing the weekly average and individual day symptom scores were mostly high or very high regardless of the day they were measured. Findings were similar when using either Spearman's rank correlation or weighted kappa method. One-day symptom scores differentiated well between World Health Organization functional classes II and III/IV pulmonary arterial hypertension and were sensitive to change in disease severity as measured by the Patient Global Assessment of Disease Severity. These data suggest that the one-day PAH-SYMPACT is feasible and appropriate for routine implementation in clinical practice.
format Online
Article
Text
id pubmed-7238840
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72388402020-06-01 Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting Frantz, Robert P. Chin, Kelly M. Zhao, Carol Flynn, Megan Badesch, David Pulm Circ Research Article Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire (PAH-SYMPACT) is the only pulmonary arterial hypertension-specific patient-reported outcomes instrument developed and validated in accordance with the US Food and Drug Administration guidance on patient-reported outcomes development. The PAH-SYMPACT tool measures pulmonary arterial hypertension-related symptoms and impact of pulmonary arterial hypertension on daily life. Symptoms are reported each day for seven consecutive days, and the impact of pulmonary arterial hypertension over one week is recalled and reported on day 7; however, daily symptom reporting may overburden patients and healthcare resources, limiting the practicality of PAH-SYMPACT outside of clinical trials. To determine the practicability of an abridged version of PAH-SYMPACT for which all reporting is completed on one day, symptom data from the SYMPHONY trial (NCT01841762; PAH-SYMPACT validation study) were retrospectively analyzed to assess whether symptoms reported on each day correlated with the weekly average and whether one-day symptom scores were sensitive to disease severity. Correlation coefficients comparing the weekly average and individual day symptom scores were mostly high or very high regardless of the day they were measured. Findings were similar when using either Spearman's rank correlation or weighted kappa method. One-day symptom scores differentiated well between World Health Organization functional classes II and III/IV pulmonary arterial hypertension and were sensitive to change in disease severity as measured by the Patient Global Assessment of Disease Severity. These data suggest that the one-day PAH-SYMPACT is feasible and appropriate for routine implementation in clinical practice. SAGE Publications 2020-05-14 /pmc/articles/PMC7238840/ /pubmed/32489644 http://dx.doi.org/10.1177/2045894020923957 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Article
Frantz, Robert P.
Chin, Kelly M.
Zhao, Carol
Flynn, Megan
Badesch, David
Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title_full Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title_fullStr Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title_full_unstemmed Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title_short Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
title_sort pulmonary arterial hypertension—symptoms and impact questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238840/
https://www.ncbi.nlm.nih.gov/pubmed/32489644
http://dx.doi.org/10.1177/2045894020923957
work_keys_str_mv AT frantzrobertp pulmonaryarterialhypertensionsymptomsandimpactquestionnairefeasibilityofutilizingonedayversussevendaysymptomreporting
AT chinkellym pulmonaryarterialhypertensionsymptomsandimpactquestionnairefeasibilityofutilizingonedayversussevendaysymptomreporting
AT zhaocarol pulmonaryarterialhypertensionsymptomsandimpactquestionnairefeasibilityofutilizingonedayversussevendaysymptomreporting
AT flynnmegan pulmonaryarterialhypertensionsymptomsandimpactquestionnairefeasibilityofutilizingonedayversussevendaysymptomreporting
AT badeschdavid pulmonaryarterialhypertensionsymptomsandimpactquestionnairefeasibilityofutilizingonedayversussevendaysymptomreporting